Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer

What is the purpose of this trial?

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.



Southwest Oncology Group (SWOG)

Start Date: 11/30/2018

End Date: 01/01/2020

Last Updated: 12/04/2018

Study HIC#: 2000024170

Get Involved

For more information about this study, contact:
Trisha Burrello
+1 203-737-2848
trisha.burrello@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image